PubMed Health⌕ Search

Biomedical subjects

M Indelli

Publications and source records attributed to M Indelli.

25 records · Page 2Linked to original sources
PubMed1984

[Therapy and follow-up of breast cancer. Experiences in 11 years of observation].

Out of 1260 biopsies performed on neoplasias of the breast in 11 years' surgical practice, 463 (36,7%) malignant tumours were encountered. The surgical strategy in the latter cases was based on two basic parameters: a) the histological report on the intraoperative biopsy; b) the clinical stage (TNM). After surgery oncological treatment followed the now universal standard practice: --T1, T2, T3, N+, M0 and T4 independent of N or M: multiple chemotherapy for 6-12 months then periodic check ups as in N- cases. --M1: multiple chemotherapy, hormone and radiation treatment combined in various ways. The results obtained in terms of trouble free periods and survival are in line with reports in the literature including those describing a larger number of cases.

Breast Neoplasms↗
PubMed1982

[Effect of antiblastic polychemotherapy (CMF) on the number of circulating monocytes in patients with breast cancer].

The behaviour of the number of circulating monocytes has been studied in 34 patients suffering from breast cancer and subjected to antiblastic polychemotherapy in accordance with the CMF pattern. In 25 patients the absolute number of monocytes fell after treatment, while in 9 it rose. The percentage of monocytopenic patients rose from 29% to 50% of the total series. The pathogenetic mechanisms of this behaviour are discussed and it is emphasized that antiblastic treatment with cytostatic drugs can be included among the causes of monocytopenia.

Adult↗
PubMed1980

Estradiol binding in rat thymus cells.

Estradiol binding in preparations of female rat thymi is demonstrated by three different approaches (dextran-coated charcoal method, immunofluorescence technique and thin-layer gel filtration). Scatchard's analysis of [3H]-estradiol proves consistent with the existence of a single class of receptor sites, having a dissociation constant (Kd) of about 2 x 10(-10) M. Steroid binding specificity in the thymus is similar to that found in the uterus. On thin-layer gel filtration the binding appears in the 8S region similar to that observed for the uterus. With the immunofluorescence sandwich technique, estradiol proves to bind to a specific cytoplasmic component that subsequently migrates into the nucleus.

Animals↗
PubMedDate not supplied

Immunometric assays of ras and c-erbB-2/neu overexpression in breast cancer: a pilot study.

The expression of the ras and c-erbB2 oncoproteins (p21 and p185, respectively), together with estrogen receptor (ER) and progesterone receptor (PgR) determination, has been retrospectively analyzed in 68 primary breast carcinomas and in 19 normal breast tissue samples. The aims of this study were: a) to explore the association between ras and c-erbB2 expression; b) to evaluate the relationship between ras and c-erbB2 expression and both steroid receptor status and the classical clinical and pathological parameters; and c) to compare two different methods for p185 determination. p185 and p21 were measured by enzyme immunoassay (EIA); p185 was also determined by Western blotting (WB); ER and PgR were assayed by radioligand binding assay. The highest value of p185 in benign breast lesions was used as the threshold to distinguish between positive and negative samples. With this threshold the c-erbB2 oncoprotein was overexpressed in 41.2% (with EIA) and in 50% (with WB) of cancer samples. The concordance rate between the two methods was 79.4. No significant association was found between p21 and p185 levels either in cancer or in normal breast tissue samples. Increasing levels of tumor p21 were associated with a shorter time to recurrence and overall survival. Increasing levels of p185 were associated with a significantly shorter time to recurrence (p185 EIA: p = 0.04, p185 WB: p = 0.029) and overall survival (p185 EIA: p = 0.04, p185 WB: p = 0.029).

Adult↗